COMP and breast cancer: Breast cancer patients who received both endocrine therapy and chemotherapy had shorter OS (HR: 2.44, p = 0.0031) when they had tumors expressing high levels of COMP compared to patients with tumors expressing low levels of COMP (Fig. 7A).